Estrella Immunopharma, Inc. (ESLA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 25, 2024, by Estrella Immunopharma, Inc., a Delaware corporation. The report addresses two separate notices received from The Nasdaq Stock Market on November 19, 2024, regarding the Company's failure to meet specific continued listing standards.
Key Financial Metrics and Listing Status
- Stockholders' Equity: Reported at $746,286 as of September 30, 2024 (per Form 10-Q).
- Minimum Stockholders' Equity Requirement: $2.5 million (Nasdaq Listing Rule 5550(b)(1)).
- Minimum Bid Price: Below $1.00 per share for 30 consecutive business days.
- Required Minimum Bid Price: $1.00 per share (Nasdaq Listing Rule 5550(a)(2)).
- Alternative Compliance Standards: The Company did not meet the alternative standards of $35 million market value of listed securities or $500,000 net income from continuing operations.
Material Changes and Deficiencies
The Company is currently non-compliant with two Nasdaq listing rules:
- Stockholders' Equity Deficiency: The Company's equity of $746,286 is significantly below the $2.5 million threshold. The Company has 45 calendar days (until January 3, 2025) to submit a compliance plan. If accepted, an extension of up to 180 days may be granted to regain compliance.
- Minimum Bid Price Deficiency: The stock price has remained below $1.00 for 30 consecutive business days. The Company has an initial 180-day grace period (until May 19, 2025) to regain compliance by maintaining a bid price of at least $1.00 for 10 consecutive business days. A second 180-day period may be available if the Company meets other listing standards and effects a reverse stock split if necessary.
Outlook, Risks, and Management Commentary
Management states it is evaluating various courses of action to regain compliance and intends to submit a plan to Nasdaq by the January 3, 2025 deadline. However, the filing explicitly states there is no assurance that a plan will be accepted or that compliance will be achieved. Failure to regain compliance or satisfy other listing requirements could result in delisting. The Company retains the right to appeal any delisting determination to a Nasdaq Hearings Panel, which would stay the delisting action pending the hearing outcome, though success is not guaranteed.
Investor Verification Checklist
- Verify the Company's submission of a compliance plan to Nasdaq by January 3, 2025.
- Monitor the daily closing bid price of ESLA to determine if it reaches $1.00 for 10 consecutive days before May 19, 2025.
- Review upcoming Form 10-Q or 10-K filings for updated stockholders' equity figures and potential capital raise activities.
- Watch for announcements regarding a potential reverse stock split to address the bid price deficiency.
- Check for any Nasdaq Hearings Panel decisions if the Company appeals a delisting determination.